[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1998042650A3 - Leukotriene antagonists useful for treating cystic fibrosis - Google Patents

Leukotriene antagonists useful for treating cystic fibrosis Download PDF

Info

Publication number
WO1998042650A3
WO1998042650A3 PCT/US1998/005455 US9805455W WO9842650A3 WO 1998042650 A3 WO1998042650 A3 WO 1998042650A3 US 9805455 W US9805455 W US 9805455W WO 9842650 A3 WO9842650 A3 WO 9842650A3
Authority
WO
WIPO (PCT)
Prior art keywords
cystic fibrosis
leukotriene antagonists
treating cystic
antagonists useful
leukotriene
Prior art date
Application number
PCT/US1998/005455
Other languages
French (fr)
Other versions
WO1998042650A2 (en
Inventor
Jerome H Fleisch
William T Jackson
Jason S Sawyer
Original Assignee
Lilly Co Eli
Jerome H Fleisch
William T Jackson
Jason S Sawyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Jerome H Fleisch, William T Jackson, Jason S Sawyer filed Critical Lilly Co Eli
Priority to AU67647/98A priority Critical patent/AU6764798A/en
Publication of WO1998042650A2 publication Critical patent/WO1998042650A2/en
Publication of WO1998042650A3 publication Critical patent/WO1998042650A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides methods for the treatment or inhibiting of the symptoms of cystic fibrosis which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B4 antagonist.
PCT/US1998/005455 1997-03-21 1998-03-19 Leukotriene antagonists useful for treating cystic fibrosis WO1998042650A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU67647/98A AU6764798A (en) 1997-03-21 1998-03-19 Leukotriene antagonists useful for treating cystic fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4087097P 1997-03-21 1997-03-21
US60/040,870 1997-03-21

Publications (2)

Publication Number Publication Date
WO1998042650A2 WO1998042650A2 (en) 1998-10-01
WO1998042650A3 true WO1998042650A3 (en) 1998-12-23

Family

ID=21913422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/005455 WO1998042650A2 (en) 1997-03-21 1998-03-19 Leukotriene antagonists useful for treating cystic fibrosis

Country Status (2)

Country Link
AU (1) AU6764798A (en)
WO (1) WO1998042650A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Combination therapy for cancer
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2007307597A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
US5543428A (en) * 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors
US5552441A (en) * 1992-12-10 1996-09-03 Eli Lilly And Company Leukotriene B4 antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
US5552441A (en) * 1992-12-10 1996-09-03 Eli Lilly And Company Leukotriene B4 antagonists
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
US5563164A (en) * 1993-12-23 1996-10-08 Eli Lilly And Company Phospholipase A2 inhibitors
US5543428A (en) * 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors

Also Published As

Publication number Publication date
AU6764798A (en) 1998-10-20
WO1998042650A2 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
BG104177A (en) Amlodipin- and atorvastatin-containing therapeutical combinations
IL135951A0 (en) Antimutagenic compositions for the treatment and prevention of photodamage to skin
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
EP1045636A4 (en) Pharmaceutical compositions and methods for the treatment of failing myocardial tissue
CA2311356A1 (en) Method for treating alzheimer's disease
WO2004050030A3 (en) Anti-sickling agents
EP0742010A3 (en) Benzoquinolin-3-ones to inhibit bone loss
ID20637A (en) METHODS FOR INHIBITING THE FORMATION OF BIOGENIC SULFIDA
WO1999005096A3 (en) Urokinase inhibitors
WO2000077206A3 (en) The myostatin gene promoter and inhibition of activation thereof
WO2000061069A3 (en) Methods and compositions for use in the treatment of hyperlipidemia
ZA9811507B (en) Combination effective for the treatment of impotence.
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
CA2338066A1 (en) Treatment of dyskinesia
WO1998042650A3 (en) Leukotriene antagonists useful for treating cystic fibrosis
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
BR9706908A (en) Compositions for the treatment of renal failure comprising l-carnosine
CA2291160A1 (en) Combination therapy for modulating the human sexual response
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
WO2002098362A3 (en) Use of rank antagonists to treat cancer
AU2001290710A1 (en) Method for increasing the effectiveness of antiinfective agents
AU1920501A (en) The use of caspase 9 inhibitors to treat ocular neural pathology

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998545814

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA